PTPRO and metabolic dysfunction-associated steatohepatitis: These showed similar results with the PTPRO deficiency leading to worse NASH, which was demonstrated by an increased body and liver weight, a pale large liver, an increased hepatocyte vacuolation, and steatosis in WD-induced NASH model and an decreased body and liver weight, a pale smaller liver, an increased hepatocyte vacuolation, and steatosis in MCD-induced NASH model (Figure 1B and Table S4-5).